← back to search

Daniel Kalman

Emory University · US
Area of research
Endocrinology · Molecular Biology
Research interest
Research interests include Escherichia coli research studies, Gut microbiota and health, Virus-based gene therapy research, and Viral gastroenteritis research and epidemiology.
h-index
44
citations
6,951
works
96
NIH funding
primary concept
email

Recent publications

Blood group A enhances SARS-CoV-2 infection
Blood 2023cited by 45position: middledoi
Blood group A enhances SARS-CoV-2 infection.
2023cited by 29position: contributordoi
The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas.
2023cited by 13position: contributordoi
A microbiota and dietary metabolite integrates DNA repair and cell death to regulate embryo viability and aneuploidy during aging.
2023cited by 9position: contributordoi
The immunoregulatory landscape of human tuberculosis granulomas
Nature Immunology 2022cited by 294position: middledoi
Vaccinia virus E3 prevents sensing of Z-RNA to block ZBP1-dependent necroptosis
Cell Host & Microbe 2021cited by 130position: middledoi
The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A
Blood Advances 2021cited by 120position: middledoi
The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A.
2021cited by 72position: contributordoi
Indoles from the commensal microbiota act via the AHR and IL-10 to tune the cellular composition of the colonic epithelium during aging
Proceedings of the National Academy of Sciences 2020cited by 144position: lastdoi
Competition between E3 and ZBP1 for Z-RNA Dictates Susceptibility to Vaccinia Virus-Induced Necroptosis
SSRN Electronic Journal 2020cited by 3position: middledoi
IMPACT-TB*: A Phase II Trial Assessing the Capacity of Low Dose Imatinib to Induce Myelopoiesis and Enhance Host Anti-Microbial Immunity Against Tuberculosis. *Imatinib Mesylate per Oral As a Clinical Therapeutic for TB
Blood 2019cited by 9position: lastdoi
Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease
Blood 2018cited by 178position: middledoi
The Evasive Enemy: Insights into the Virulence and Epidemiology of the Emerging Attaching and Effacing Pathogen<i>Escherichia albertii</i>
Infection and Immunity 2018cited by 36position: middledoi
Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents
BMC Pharmacology and Toxicology 2018cited by 17position: middledoi
Layered defense: how mucus and tight junctions seal the intestinal barrier
Journal of Molecular Medicine 2017cited by 362position: lastdoi
In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of<i>Mycobacterium tuberculosis</i>
Proceedings of the National Academy of Sciences 2017cited by 208position: middledoi
Indoles from commensal bacteria extend healthspan
Proceedings of the National Academy of Sciences 2017cited by 192position: lastdoi
Inhibition of DAI-dependent necroptosis by the Z-DNA binding domain of the vaccinia virus innate immune evasion protein, E3
Proceedings of the National Academy of Sciences 2017cited by 144position: middledoi
Monocarbonyl analogs of curcumin inhibit growth of antibiotic sensitive and resistant strains of Mycobacterium tuberculosis
European Journal of Medicinal Chemistry 2015cited by 82position: lastdoi
Low Doses of Imatinib Induce Myelopoiesis and Enhance Host Anti-microbial Immunity
PLoS Pathogens 2015cited by 76position: lastdoi
New tricks for old dogs: countering antibiotic resistance in tuberculosis with host‐directed therapeutics
Immunological Reviews 2015cited by 68position: lastdoi
A Family of Indoles Regulate Virulence and Shiga Toxin Production in Pathogenic E. coli
PLoS ONE 2013cited by 96position: lastdoi
Intestinal Epithelial CD98 Directly Modulates the Innate Host Response to Enteric Bacterial Pathogens
Infection and Immunity 2013cited by 36position: middledoi
Productive Replication of Ebola Virus Is Regulated by the c-Abl1 Tyrosine Kinase
Science Translational Medicine 2012cited by 126position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Alyson Swimm · Emory University6 papers (2013–2020)Domonica N. Powell · Emory University4 papers (2017–2020) · 4 papers (2021–2023)Jason W. Upton · Auburn University3 papers (2017–2021)Samantha Cotsmire · Arizona State University3 papers (2017–2021)Edward S. Mocarski · Emory University3 papers (2017–2021)Robert Sonowal · Emory University3 papers (2017–2020)Cynthia R. Giver · Emory University3 papers (2015–2019)Christopher Capaldo · Hawaii Pacific University3 papers (2017–2018)Heather Koehler · Washington State University3 papers (2017–2021)Bertram L. Jacobs · Arizona State University3 papers (2017–2021)Edmund K. Waller · Emory University3 papers (2015–2019)Ruth J. Napier · VA Portland Health Care System2 papers (2015–2015)Jeffrey Langland · Arizona State University2 papers (2017–2020)Richard D. Cummings · Beth Israel Deaconess Medical Center2 papers (2021–2023)Deepak Kaushal · Instituto Nacional de Enfermedades Respiratorias2 papers (2017–2019)Siddharth Balachandran · Temple University Health System2 papers (2020–2021)Shang‐Chuen Wu · Brigham and Women's Hospital2 papers (2021–2023)Hans Verkerke · Emory University2 papers (2021–2023)Bettina Bommarius · Georgia Institute of Technology2 papers (2013–2015)